ArticleThe oncologist2024

Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication.

Riccardo Giovanni Borroni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.